Ophthalmic Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Expansion of Integrated Ophthalmology-Primary Care Clinics in Emerging Markets

Integrated eye-care hubs across India, China, and Southeast Asia embed tonometry, fundus photography, and visual-acuity tests into routine wellness visits, shortening referral cycles from six weeks to two days. India’s National Programme for Control of Blindness established 1,200 vision centers in 2024, each linked via tele-ophthalmology to tertiary hospitals, enabling the early detection of glaucoma and retinopathy while boosting equipment utilization for portable slit lamps and autorefractors^{[1]Ministry of Health and Family Welfare, India, “National Programme for Control of Blindness,” mohfw.gov.in}. China’s Healthy China 2030 blueprint mandates annual eye exams for citizens over 60, stimulating the purchase of compact OCTs and handheld tonometers in township clinics that previously lacked ophthalmic capital assets. Private chains, such as Aravind Eye Care, offer turnkey clinic franchises that bundle diagnostics, EMR platforms, and workforce training, thereby accelerating ophthalmic device market penetration across Tier-2 and Tier-3 cities. Earlier detection pulls surgical volume forward, lifting cataract and MIGS procedures while lowering lifetime treatment costs, giving policymakers fiscal incentives to expand the model.

Growing Adoption of AI-Enabled Diagnostic Imaging Systems

Autonomous AI algorithms for diabetic retinopathy and AMD have received FDA and CE clearances, empowering primary-care teams to execute point-of-care retinal scans with over 90% sensitivity in under 60 seconds, comparable to the performance of retina specialists. EyeArt deployments reached over 900 U.S. sites by mid-2025, resulting in a 40% increase in retinopathy detection compared to legacy referral pathways, as patients receive same-visit results and immediate care plans. Payers reimburse USD 50–75 per AI scan, compared to USD 150 for specialist consultations, catalyzing rapid uptake in cost-conscious systems and reinforcing preventive care contracts. The technology also addresses workforce deficits, with the American Academy of Ophthalmology forecasting a shortage of 4,000 retina specialists by 2030, allowing specialists to focus on managing complex therapeutics while AI screens routine cases^{[2]American Academy of Ophthalmology, “2025 Workforce Projections,” aao.org}. Vendors now integrate AI modules directly into OCT and fundus platforms, converting hardware into software-upgradable assets and anchoring long-term service revenues.

Rising Prevalence of Vision Disorders in Aging Populations

Global citizens aged 60+ will climb to 1.4 billion by 2030, driving cataract prevalence past 32 million and glaucoma cases toward 112 million by 2031. Japan and South Korea already log more than 1.5 million cataract surgeries per year, sustaining premium IOL demand despite reimbursement headwinds. China’s seniors are projected to reach 400 million by 2035, triggering an exponential increase in purchases of phacoemulsification units and MIGS micro-stents, as domestic manufacturers capture a 20% share by offering price points 40% lower than those of their international counterparts. High-income nations face an escalation of AMD, which doubled between 2010 and 2025, fueling anti-VEGF injection kit volumes and the adoption of sustained-release implants. Aging demographics, therefore, guarantee procedure growth even when device ASPs moderate under competitive pressure, underpinning the long-run outlook for the ophthalmic devices market.

Surge in Employer-Funded Digital Eye-Health Wellness Programs

Corporations in North America and Europe embed smartphone-based vision tests into annual wellness checks, citing productivity gains once refractive errors are corrected. VSP Vision Care and EyeMed rolled out remote refraction apps in 2024, enabling employees to obtain prescriptions without in-person clinic visits and order lenses directly, thereby increasing the utilization of daily-disposable contacts. Johnson & Johnson Vision installed on-site screening kiosks at Fortune 500 campuses, identifying undiagnosed intraocular pressure spikes in 18% of the screened staff, catalyzing early glaucoma referrals. Employers report a 3:1 return on investment within 18 months owing to fewer visual-error-related mistakes and reduced absenteeism. Pilot programs have been implemented in Singapore and the UAE, signaling potential global expansion that will increase the ophthalmic devices market.

High Capital Cost of Advanced Ophthalmic Equipment

Femtosecond lasers listed above USD 500,000 and swept-source OCT systems run USD 120,000–150,000, pricing out independent practices that perform fewer than 200 cataract surgeries per year, despite leasing programs that still demand USD 8,000–12,000 monthly^{[3]American Society of Cataract and Refractive Surgery, “Capital Cost Survey 2025,” ascrs.org}. Public hospitals in India and Indonesia allocate under USD 50,000 annually for ophthalmic capital expenditure, delaying upgrades by half a decade and concentrating technology in urban centers. Zeiss launched a USD 75,000 OCT variant in 2025, trading scan density for affordability, but image-quality compromises slow uptake among clinicians sensitive to diagnostic accuracy. Capital hurdles thus curb the penetration of next-generation devices and temper the growth of the ophthalmic devices market in price-constrained geographies.

Rising Cybersecurity Risks in Connected Diagnostic Devices

Fourteen ransomware incidents at U.S. eye-care networks in 2024 exposed vulnerabilities in networked OCT and fundus cameras, prompting the FDA to draft guidance mandating secure boot protocols and software bills of materials. Compliance extends clearance timelines by up to 18 months and adds USD 2–3 million per product line, favoring large OEMs with in-house security teams. Hospitals now require third-party penetration tests before procurement, which stretches sales cycles and increases working-capital demands on smaller vendors. Legacy devices, about 40% of installed fleets, cannot accept firmware patches, forcing practices to weigh replacement costs against operational continuity, a dilemma that restrains ophthalmic devices market refresh rates.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: Diagnostics Outpace Vision Care in Growth

Diagnostic & monitoring devices generated robust demand, advancing at an 8.65% CAGR from 2026 to 2031, significantly faster than overall ophthalmic devices market expansion. Swept-source OCT and widefield fundus cameras deliver tenfold faster scans than time-domain units, unlocking earlier choroidal neovascularization detection and guiding anti-VEGF therapy escalation. Hand-held tonometers priced below USD 5,000 extend glaucoma screening into pharmacies and primary-care clinics across the Asia Pacific, broadening the installed base underpinning the ophthalmic devices market size for diagnostics. In contrast, Vision Care Devices retained 62.34% of 2025 revenue but faces ASP erosion as direct-to-consumer disruptors cut spectacle and contact lens margins by 30–40%.

Vision care remains volume-dominant, buoyed by urban myopia prevalence exceeding 50% in China and South Korea; however, slower growth will gradually reduce its contribution to the ophthalmic devices market share over time. CooperVision’s MiSight lenses, which curb axial elongation by 50% over three years, generated USD 120 million in sales in 2025, illustrating a willingness to pay for clinically differentiated products despite price sensitivity. Smart contact lenses with embedded glucose and pressure sensors are slated for 2027 launches, promising new revenue streams but facing regulatory complexity that could temper the near-term growth of the ophthalmic devices market. Surgical devices are growing moderately as ASCs opt for refurbished machines bundled with consumables. This model locks practices into long-term contracts, thereby impeding the displacement of new entrants by incumbents.

By Disease Indication: Diabetic Retinopathy Gains Momentum

Cataract surgeries captured 38.41% of the 2025 disease-indication revenue, driven by aging demographics and widespread access to phacoemulsification. In contrast, diabetic retinopathy is expected to command the fastest expansion at a 7.82% CAGR through 2031. Autonomous AI screening slashes per-patient costs from USD 150 to USD 50, enabling payers to mandate annual retinal scans in diabetes care plans, which boosts the ophthalmic devices market size associated with fundus imaging and OCT. The rising prevalence of diabetes, projected to affect 643 million adults by 2030, escalates demand for OCT, injection kits, and sustained-release implants, such as Genentech’s Susvimo, which halves the injection frequency and improves compliance.

Glaucoma interventions via MIGS and laser trabeculoplasty are also advancing steadily, with Glaukos and Alcon securing a 60% U.S. share in 2025, owing to favorable Medicare codes that reimburse USD 1,200–1,500 per procedure. Anti-VEGF therapies for AMD generated USD 6 billion in device-linked revenue from injection systems in 2025, demonstrating sizable but mature spend patterns relative to faster-growing diabetic retinopathy. Large emerging markets, such as India and China, are expected to exceed 15 million cataract procedures annually by 2030, supporting the uptake of premium IOLs and femtosecond lasers, albeit at ASPs 40% below Western pricing due to domestic competition. This will expand the ophthalmic devices market size, albeit at the expense of diluting the gains for multinationals.

By End-User: ASCs Capture Share from Hospitals

Hospitals accounted for 42.74% of 2025 revenue, reflecting complex cases that require overnight monitoring, but ambulatory surgery centers are rising at a 7.67% CAGR to 2031 as Medicare’s site-neutral payments erase historical hospital premiums and accelerate ophthalmic devices market migration. ASCs conduct 15-minute cataract procedures versus 45-minute hospital sessions, thereby elevating daily case counts and boosting the return on capital for femtosecond lasers, which are priced at USD 500,000.

Specialty ophthalmic clinics capture a 30% share in 2025 by focusing on refractive and cosmetic surgeries, which are often financed out-of-pocket, thereby insulating revenue from payer cuts and fostering the rapid adoption of high-margin femtosecond lasers and premium IOLs. Optical retail chains integrate autorefractors and tele-optometry links to deliver prescriptions within 20 minutes, siphoning routine eye-exam traffic away from clinics and widening the ophthalmic devices market as chains expand internationally. Hospitals retain dominance in complex pediatric and vitreoretinal surgery; however, routine diagnostics and cataract workflows continue to shift toward ASCs and clinics, redistributing the ophthalmic devices market share across care settings.

Geography Analysis

North America Ophthalmic Devices Market

North America accounted for 39.94% of 2025 revenue, driven by Medicare funding for advanced imaging and MIGS devices. However, saturation limits growth to mid-single digits, as cataract penetration surpasses 90% of eligible patients. Autonomous AI screening approvals and 18 ophthalmic device clearances in 2024 sustain innovation, but the adoption of refurbished equipment and bundled contracts exerts pricing pressure on OEMs. Canada’s single-payer model constrains capital budgets for premium OCT and femtosecond lasers, shifting upgrade demand to private clinics serving self-pay patients willing to fund rapid access to advanced procedures.

APAC Ophthalmic Devices Market

The Asia Pacific is the fastest-growing region, with a 7.12% CAGR through 2031, driven by China’s Healthy China 2030 annual examination mandate and India’s rollout of 1,200 vision screening centers, which together add millions of diagnostic encounters each year. Japan and South Korea perform more than 1.5 million cataract surgeries annually, maintaining a high consumable pull-through for premium IOLs despite moderating device ASPs. Domestic manufacturers such as MOPTIM and Suowei captured 20% of China’s phacoemulsification systems market in 2025 by offering units at USD 30,000, a 50% discount to Western brands, and exporting to Southeast Asia, thereby expanding the regional ophthalmic devices market size. Rising medical tourism in Thailand and Singapore further scales the volume of refractive surgery, bundling LASIK with hospitality packages that attract regional patients and bolster sales of femtosecond lasers.

EMEA and South America Ophthalmic Devices Market

Europe generated 25% of global revenue in 2025; however, EU MDR compliance delayed 30% of planned product launches, temporarily constricting replenishment cycles and increasing refurbishment demand. NHS cataract wait times exceeding 18 months prompted private-sector chains, such as Optegra, to charge GBP 2,500 (USD 3,200) per eye for expedited surgery, stimulating demand for premium lenses and reinforcing the ophthalmic devices market in the UK . The Middle East & Africa and South America remain underpenetrated, with a 5% CAGR, as public systems focus on basic cataract interventions. However, mobile eye clinics and tele-diagnostics are expanding their reach into rural areas, setting the stage for the future growth of portable devices priced under USD 10,000.

Regulatory Landscape

Ophthalmic devices face increasingly divergent regulatory pathways across major markets, especially for drug-device combinations used in retinal therapy and glaucoma. In the United States, FDA oversight for certain ophthalmic products packaged with dispensers is anchored in combination product requirements under 21 CFR Part 4, which raises quality-system and documentation expectations for manufacturers accustomed to device-only workflows. In the European Union, EU Regulation 2017/745 (MDR) interacts with the medicinal-products framework for integral drug-device combinations, with EMA noting that device components must meet relevant MDR General Safety and Performance Requirements and be CE marked when used with medicinal products.

Standards updates also continue to shape technical compliance and labeling for key ophthalmic categories. ISO 15004-1:2020 (general requirements for ophthalmic instruments) was confirmed in September 2025, reinforcing baseline safety and performance expectations for diagnostic and surgical instruments. For intraocular lenses, ISO 11979-4:2026 (labeling and information) was published in February 2026, tightening requirements around IOL information provided to clinicians and patients and increasing conformity work for premium IOL portfolios being expanded by large OEMs.

Value Chain Analysis

The ophthalmic devices value chain extends from specialty optical components and precision manufacturing through regulated assembly, sterilization, and multi-channel distribution into hospitals, ambulatory surgery centers, clinics, and optical retail. Upstream inputs include lenses, coatings, sensors, micro-mechanical components, and electronics used in connected OCT and fundus platforms, while midstream work centers on OEM design controls, verification and validation, and manufacturing of capital equipment (diagnostic and surgical platforms) alongside high-volume consumables (IOLs, contact lenses, and single-use surgical packs). Downstream, distributors and integrated OEM service organizations support installation, calibration, training, and recurring software and service contracts, reflecting the market shift toward bundled offerings that combine hardware, consumables, and analytics.

For drug-device combinations and delivery-related ophthalmology products, value creation depends on coordinated execution across pharma or biotech sponsors, specialized device manufacturers, and contract manufacturers with combination-product experience. Under the FDA policy posture for certain ophthalmic products under 21 CFR Part 4, the importance of cGMP-aligned packaging and primary container systems (including dispensers) increases, and integration burden grows across formulation, container-closure integrity, and device mechanics. Sterility assurance and in-transit integrity for prefilled systems and implantables act as practical bottlenecks, while regulatory documentation and testing requirements add time and cost that favor well-capitalized OEMs and partners able to handle dual-regime expectations across FDA and EU MDR/EMA workflows.

Market Opportunities and Future Outlook

Premium cataract and refractive workflows are creating whitespace for differentiated IOL designs, parameter expansion, and surgical-platform upgrades as care continues moving toward higher-throughput sites. In 2026, major OEM activity reinforced this direction, with Alcon launching the Clareon TruPlus monofocal and toric IOL line and introducing the UNITY Cataract System in Canada, and Johnson & Johnson expanding US commercial availability of the TECNIS PureSee IOL. Together, these moves support opportunities for suppliers that help enable faster ASC-compatible workflows, digital planning and postoperative management, and consumable pull-through tied to installed platforms.

Sustained-delivery retinal and glaucoma approaches are also driving investment and reimbursement experimentation in drug-device integrated platforms, where value sits across implants, delivery systems, and enabling diagnostics used for chronic-disease management. In May 2026, the AMA CPT Editorial Panel approved a new add-on Category III CPT code for SpyGlass Pharma's bimatoprost drug pad-IOL system, pointing to an active pathway for coding and evidence generation around implantable, long-acting therapies. Capital allocation continues to move toward long-acting ocular delivery, as Bayer signed a definitive agreement in May 2026 to acquire Perfuse Therapeutics for up to USD 2.45 billion, centered on an intravitreal implant program. In Japan, Chugai filed in March 2026 for the medical device component of its port delivery platform with ranibizumab, underscoring ongoing pipeline and regulatory momentum for combination products designed to reduce injection burden.